Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 5/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542699 | 0.75 | TAAR1 (0.50) | MIFIDO1LOXL2TAAR1PLA2G1B | |
| SCHEMBL5537412 | 0.74 | TAAR1 (0.42) | IDO1TAAR1MAOBPYCR1 | |
| SCHEMBL11690460 | 0.74 | IDO1 (0.46) | IDO1TAAR1AGXTALDH1A1PYCR1 | |
| SCHEMBL2952783 | 0.74 | MIF (0.48) | MIFIDO1TAAR1AGXTMAOB | |
| SCHEMBL96029 | 0.74 | TAAR1 (0.48) | MIFIDO1LOXL2TAAR1PLA2G1B | |
| SCHEMBL18244863 | 0.74 | IDO1 (0.46) | MIFIDO1LOXL2TAAR1PLA2G1B | |
| SCHEMBL5537375 | 0.74 | IDO1 (0.41) | MIFIDO1 | |
| SCHEMBL9331371 | 0.74 | TRPA1 (0.52) | MIFIDO1TAAR1ALDH1A1LMNA | |
| SCHEMBL37742 | 0.74 | IDO1 (0.46) | MIFIDO1LOXL2TAAR1PLA2G1B | |
| SCHEMBL10778175 | 0.74 | HRH3 (0.50) | LOXL2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160396-B1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2476689-B1 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9067961-B2 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| CN-101784556-B | Thiocarbon-protecting groups for rna synthesis | AGILENT TECHNOLOGIES INC | 2014-07-09 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120238737-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| EP-2476689-A1 | Thiocarbon-protecting groups for RNA synthesis | Agilent Technologies, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8202983-B2 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| CN-101784556-A | thiocarbon-protecting groups for rna synthesis | AGILENT TECHNOLOGIES INC | 2010-07-21 | — | — | CN | disclosed |
| WO-2008141248-A2 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0244195-A1 | 2-Vinylpenams and process | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 1987-11-04 | — | — | EP | disclosed |
| US-4604386-A | CONTROL OF GRAMPOSITIVE BACTERIA | ELI LILLY AND COMPANY (US) | 1986-08-05 | — | — | US | disclosed |
| EP-0168222-A2 | 3-(Alkynylalkyloxy) Cephalosporins | ELI LILLY AND COMPANY (US) | 1986-01-15 | — | — | EP | disclosed |
| US-4560749-A | ANTIBIOTICS, BACTERICIDES | ELI LILLY AND COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| US-4521598-A | 3-Azidocephalosporins | ELI LILLY AND COMPANY (US) | 1985-06-04 | — | — | US | disclosed |
| EP-0136177-A2 | 3-Azidocephalosporins as intermediates and novel antibacterial agents | ELI LILLY AND COMPANY (US) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238737-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | NSUN3, NSUN2, TRDMT1 | MIF 1143/4885IDO1 1145/4885LOXL2 4389/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MIF 1824/4885IDO1 3181/4885LOXL2 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.